Latest / Stock Movers / Nvidia Down, General Mills Lower, Eli Lilly Up on GLP-1 Pill Performance
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The.
- 0:08Speaker 2: Stock Movers Report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market, harnessing the power of Bloomberg Data.
- 0:17Speaker 1: Let's take a look at some of the stocks on
- 0:18Speaker 1: the move today on Paul Swenya alongside Alexis Christopherus and
- 0:21Speaker 1: we're joined by Bloomberg's Christina. You know, Christine, what are
- 0:24Speaker 1: you looking at today? Well, well, let's talk about in
- 0:26Speaker 1: Video because that is the one stock that is on
- 0:29Speaker 1: everybody's minds this morning. So ticker NVDA. Those shares are
- 0:33Speaker 1: down more than two percent, two and a half percent
- 0:35Speaker 1: at the moment, actually, and that is because we did
- 0:38Speaker 1: get that reporting from the Financial Times saying that China's
- 0:42Speaker 1: Internet regulator has told the country's biggest technology companies to
- 0:45Speaker 1: stop buying in Vidia chips, specifically the rtx pro six
- 0:50Speaker 1: thousand D chips. Now, this chip isn't regarded as among
- 0:54Speaker 1: in Vidia's marquee products. It's more of a high end card.
- 0:57Speaker 1: They designed it specifically for the restricted Chinese market. But
- 1:01Speaker 1: now we have this order from the Chinese authorities telling
- 1:05Speaker 1: their biggest companies to not buy the jit We did
- 1:08Speaker 1: get a report from the BBC quoting and Viga CEO
- 1:12Speaker 1: Jensen Huang saying that he's quote disappointed by the ruling
- 1:16Speaker 1: and that he would be quote patients in responding to
- 1:18Speaker 1: it right. Also, Christine, General Mills, I guess benefiting from
- 1:22Speaker 1: the fact that more folks are eating at home, they're
- 1:25Speaker 1: eating out less.
- 1:26Speaker 2: But I'm looking at the stock, it's not doing much
- 1:27Speaker 2: of anything right now.
- 1:28Speaker 1: Yeah, absolutely, Alexi sits down, So ticker gis General Mills
- 1:33Speaker 1: shares down just a tenth of one percent at the moment.
- 1:36Speaker 1: So clearly the first quarter adjusted EPs beat not doing
- 1:41Speaker 1: much to lift that stock at the moment, but they
- 1:43Speaker 1: did get that beat. It's eighty six cents topping analyst estimates.
- 1:46Speaker 1: In the company was saying that is indeed the rise
- 1:50Speaker 1: of home cooking among value conscious consumers that are struggling
- 1:54Speaker 1: with inflation. That has helped some of their segments, including
- 1:57Speaker 1: rice and beans. But at the same time, there is
- 2:00Speaker 1: kind of a warning in there. They did say that
- 2:02Speaker 1: sales in North America retail segment dropped thirteen percent for
- 2:06Speaker 1: the quarter to two point six billion, So that's probably
- 2:08Speaker 1: people substituting in store brands for name brands.
- 2:13Speaker 2: I know, I am I know, I am and I
- 2:15Speaker 2: am all of that the last four or five years.
- 2:17Speaker 1: Yeah, So that's probably why we're not getting much of
- 2:20Speaker 1: a lift because there is it's a bit of a
- 2:22Speaker 1: double edged sword kind of report from General Mills today.
- 2:25Speaker 1: You spend generations building up brand value and then puff gone.
- 2:30Speaker 1: That's what a little inflation will take. That's what a
- 2:32Speaker 1: little inflation to do. L l y Eli Lilly, l
- 2:35Speaker 1: y Eli Lilly. So those shares not up by much,
- 2:38Speaker 1: just about to four tens of one percent at the moment.
- 2:41Speaker 1: But they did get good news from a trial of
- 2:44Speaker 1: their golp one drug. It's an oral drug, experimental diabetes pill,
- 2:49Speaker 1: which showed that people on this for the trial lost
- 2:53Speaker 1: more weight and had a better blood sugar control than
- 2:56Speaker 1: those in an older approved rival from Novo Nordisk. So
- 3:00Speaker 1: this is a head to it drug trial. Patients that
- 3:02Speaker 1: were given Eli Lilly's oral drug lost eight point two
- 3:06Speaker 1: percent of their body weight in fifty two weeks versus
- 3:09Speaker 1: five point three percent for the Novo drug. So doctors
- 3:12Speaker 1: who were kind of they presented the results of doctors
- 3:15Speaker 1: and the doctors saying that the results look positive. They
- 3:18Speaker 1: say that the tablet will make it possible to treat
- 3:20Speaker 1: more patients because it's easier to produce and to take
- 3:23Speaker 1: given that it is an oral drug.
- 3:25Speaker 2: The Stock Mover's report from Bloomberg Radio. Check back with
- 3:30Speaker 2: us throughout the day for the latest roundup of companies
- 3:32Speaker 2: making news on Wall Street and for the latest market
- 3:35Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:40Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:43Speaker 2: the Bloomberg Business app.